Non-viral Vectors For Targeted Delivery Of RNAi Nucleotides To Cervical Cancers
Funder
National Health and Medical Research Council
Funding Amount
$415,738.00
Summary
RNA interference (or gene silencing) is a new technique whereby we are able to turn off the expression of a particular gene either temporarily or permanently. Cancer is basically a genetic disease where certain protective genes are lost or cancer-causing genes expressed. Gene silencing holds great promise in the treatment of genetic disorders, infectious diseases and cancer. Cervical cancer is caused by infection with the human papillomavirus and the expression of two cancer-causing genes. Using ....RNA interference (or gene silencing) is a new technique whereby we are able to turn off the expression of a particular gene either temporarily or permanently. Cancer is basically a genetic disease where certain protective genes are lost or cancer-causing genes expressed. Gene silencing holds great promise in the treatment of genetic disorders, infectious diseases and cancer. Cervical cancer is caused by infection with the human papillomavirus and the expression of two cancer-causing genes. Using RNA interference we can turn off the expression of these two genes which results in the death of the cancer cell. We are also able to cure mice of tumours derived from human cervical cancer. The major issue with gene silencing is how to deliver it effectively to patients. Here we are investigating novel nanoparticulate systems to deliver this new gene-inhibiting drugs preferentially to the tumour site.Read moreRead less
Development of an immunology toolbox to combat emerging marsupial diseases. Disease is increasingly a driver of wildlife population declines in Australia. However, basic immunology tools for >99% of vertebrate species are scarce, limiting our ability to prevent and respond to emerging and endemic diseases, such as devil facial tumour disease and wobbly possum disease. The overarching goal of this project is to improve wildlife health and fill the marsupial immunology gap by developing a long-ove ....Development of an immunology toolbox to combat emerging marsupial diseases. Disease is increasingly a driver of wildlife population declines in Australia. However, basic immunology tools for >99% of vertebrate species are scarce, limiting our ability to prevent and respond to emerging and endemic diseases, such as devil facial tumour disease and wobbly possum disease. The overarching goal of this project is to improve wildlife health and fill the marsupial immunology gap by developing a long-overdue multispecies marsupial immunology toolbox. The toolbox is needed to accelerate devil facial tumour disease vaccine progress and conservation immunology research. It will expand our knowledge of wobbly possum disease virus that is increasingly reported in Tasmania and the risk posed by the virus to other possum species.Read moreRead less
Identifying Long-range Regulatory Elements Of The Breast Cancer Susceptibility Gene, BRCA1
Funder
National Health and Medical Research Council
Funding Amount
$612,842.00
Summary
BRCA1 is a breast cancer susceptibility gene implicated in both familial and sporadic breast cancers. The mechanisms controlling BRCA1 expression are poorly understood. We will identify DNA sequences critical for regulation of the BRCA1 gene. We hypothesise that these regions are mutational hot spots conferring an increased breast cancer risk. A better understanding of the pathways responsible for promoting BRCA1-associated breast cancer will provide important diagnostic and treatment targets.
Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies. Cancer persists as a major cause of morbidity and mortality globally. A major problem is the non-specific action of drugs used for treatment. The minicell is a drug delivery vehicle, capable of packaging a variety of drugs. The project will develop tumour-specific antibodies that will target minicells to tumours, improving cancer survival rates.